Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 9.80 -0.05 (-0.51%)
As of 09/28/2026 11:38 AM Eastern
Compare

CRTX vs. KAV, BRES, RLD, EMH, and FAR

Should you buy CRISM Therapeutics stock or one of its competitors? CRISM Therapeutics's main competitors and comparable companies include Kavango Resources (KAV), Blencowe Resources (BRES), Richland Resources Ltd (RLD.L) (RLD), European Metals (EMH), and Ferro-Alloy Resources (FAR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "metals & mining" industry.

How does CRISM Therapeutics compare to Kavango Resources?

CRISM Therapeutics (LON:CRTX) and Kavango Resources (LON:KAV) are both small-cap materials companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, Kavango Resources had 2 more articles in the media than CRISM Therapeutics. MarketBeat recorded 2 mentions for Kavango Resources and 0 mentions for CRISM Therapeutics. CRISM Therapeutics' average media sentiment score of 0.69 beat Kavango Resources' score of 0.00 indicating that CRISM Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CRISM Therapeutics Positive
Kavango Resources Neutral

CRISM Therapeutics has a beta of 0.583, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Kavango Resources has a beta of 0.288, indicating that its stock price is 71% less volatile than the broader market.

Kavango Resources has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Kavango Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£352K22.05-£792.20K-£5.10N/A
Kavango Resources£3.32M8.68-£5.48K-£0.48N/A

CRISM Therapeutics has a net margin of 0.00% compared to Kavango Resources' net margin of -323.58%. Kavango Resources' return on equity of -41.48% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -119.45% -26.77%
Kavango Resources -323.58%-41.48%-14.06%

0.3% of CRISM Therapeutics shares are held by institutional investors. 50.5% of CRISM Therapeutics shares are held by company insiders. Comparatively, 8.6% of Kavango Resources shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Kavango Resources beats CRISM Therapeutics on 7 of the 13 factors compared between the two stocks.

How does CRISM Therapeutics compare to Blencowe Resources?

CRISM Therapeutics (LON:CRTX) and Blencowe Resources (LON:BRES) are both small-cap materials companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, CRISM Therapeutics' average media sentiment score of 0.69 beat Blencowe Resources' score of 0.00 indicating that CRISM Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CRISM Therapeutics Positive
Blencowe Resources Neutral

0.3% of CRISM Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Blencowe Resources shares are held by institutional investors. 50.5% of CRISM Therapeutics shares are held by insiders. Comparatively, 6.2% of Blencowe Resources shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CRISM Therapeutics has higher revenue and earnings than Blencowe Resources. Blencowe Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£352K22.05-£792.20K-£5.10N/A
Blencowe ResourcesN/AN/A-£1.28M-£0.76N/A

CRISM Therapeutics has a beta of 0.583, indicating that its share price is 42% less volatile than the broader market. Comparatively, Blencowe Resources has a beta of 1.449, indicating that its share price is 45% more volatile than the broader market.

Blencowe Resources' return on equity of -19.76% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -119.45% -26.77%
Blencowe Resources N/A -19.76%-13.34%

Summary

CRISM Therapeutics and Blencowe Resources tied by winning 5 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Richland Resources Ltd (RLD.L)?

CRISM Therapeutics (LON:CRTX) and Richland Resources Ltd (RLD.L) (LON:RLD) are both small-cap materials companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

0.3% of CRISM Therapeutics shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Richland Resources Ltd (RLD.L)'s return on equity of 0.00% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -119.45% -26.77%
Richland Resources Ltd (RLD.L) N/A N/A N/A

In the previous week, CRISM Therapeutics' average media sentiment score of 0.69 beat Richland Resources Ltd (RLD.L)'s score of 0.00 indicating that CRISM Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CRISM Therapeutics Positive
Richland Resources Ltd (RLD.L) Neutral

Richland Resources Ltd (RLD.L) has lower revenue, but higher earnings than CRISM Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£352K22.05-£792.20K-£5.10N/A
Richland Resources Ltd (RLD.L)£19K0.00N/AN/AN/A

Summary

CRISM Therapeutics beats Richland Resources Ltd (RLD.L) on 5 of the 7 factors compared between the two stocks.

How does CRISM Therapeutics compare to European Metals?

European Metals (LON:EMH) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, European Metals had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for European Metals and 0 mentions for CRISM Therapeutics. CRISM Therapeutics' average media sentiment score of 0.69 beat European Metals' score of -0.15 indicating that CRISM Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
European Metals Neutral
CRISM Therapeutics Positive

CRISM Therapeutics has higher revenue and earnings than European Metals. European Metals is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
European MetalsN/AN/A-£2.30M-£3.81N/A
CRISM Therapeutics£352K22.05-£792.20K-£5.10N/A

1.9% of European Metals shares are held by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are held by institutional investors. 1.2% of European Metals shares are held by company insiders. Comparatively, 50.5% of CRISM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CRISM Therapeutics has a net margin of 0.00% compared to European Metals' net margin of -287.87%. European Metals' return on equity of -25.49% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
European Metals-287.87% -25.49% -2.47%
CRISM Therapeutics N/A -119.45%-26.77%

European Metals has a beta of 0.291, indicating that its share price is 71% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.583, indicating that its share price is 42% less volatile than the broader market.

Summary

CRISM Therapeutics beats European Metals on 7 of the 12 factors compared between the two stocks.

How does CRISM Therapeutics compare to Ferro-Alloy Resources?

Ferro-Alloy Resources (LON:FAR) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Ferro-Alloy Resources has a beta of 0.818, suggesting that its share price is 18% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.583, suggesting that its share price is 42% less volatile than the broader market.

CRISM Therapeutics has lower revenue, but higher earnings than Ferro-Alloy Resources. Ferro-Alloy Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ferro-Alloy Resources£4.53M8.80-£9.69M-£1.70N/A
CRISM Therapeutics£352K22.05-£792.20K-£5.10N/A

CRISM Therapeutics has a net margin of 0.00% compared to Ferro-Alloy Resources' net margin of -185.72%. Ferro-Alloy Resources' return on equity of 283.86% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ferro-Alloy Resources-185.72% 283.86% -21.47%
CRISM Therapeutics N/A -119.45%-26.77%

Ferro-Alloy Resources currently has a consensus target price of GBX 30, indicating a potential upside of 468.18%. Given Ferro-Alloy Resources' stronger consensus rating and higher probable upside, equities research analysts plainly believe Ferro-Alloy Resources is more favorable than CRISM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ferro-Alloy Resources
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
CRISM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Ferro-Alloy Resources had 4 more articles in the media than CRISM Therapeutics. MarketBeat recorded 4 mentions for Ferro-Alloy Resources and 0 mentions for CRISM Therapeutics. CRISM Therapeutics' average media sentiment score of 0.69 beat Ferro-Alloy Resources' score of -0.34 indicating that CRISM Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Ferro-Alloy Resources Neutral
CRISM Therapeutics Positive

0.5% of Ferro-Alloy Resources shares are held by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are held by institutional investors. 59.1% of Ferro-Alloy Resources shares are held by insiders. Comparatively, 50.5% of CRISM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Ferro-Alloy Resources beats CRISM Therapeutics on 11 of the 16 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsMetals & Mining IndustryMaterials SectorLON Exchange
Market Cap£7.76M£3.81B£4.81B£2.89B
Dividend YieldN/A5.23%4.73%6.22%
P/E Ratio-1.9225.1225.44366.61
Price / Sales22.0527,834.7116,536.7089,510.94
Price / CashN/A26.4924.5027.89
Price / Book0.2312.1110.066.33
Net Income-£792.20K£127.13M£157.81M£5.89B
7 Day Performance2.30%-3.27%-2.91%-0.15%
1 Month Performance-14.04%-4.12%-3.94%10.98%
1 Year Performance-10.42%24.74%21.22%18.44%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 9.80
-0.5%		N/A+16.0%£7.76M£352KN/A4
KAV
Kavango Resources
N/AGBX 0.74
+5.3%		N/A-37.3%£30.56M£1.72MN/A43
BRES
Blencowe Resources
N/AGBX 5.82
-2.0%		N/A-1.7%£29.78MN/AN/A3
RLD
Richland Resources Ltd (RLD.L)
N/AN/AN/AN/A£29.09M£19KN/A2,730
EMH
European Metals
N/AGBX 11.75
flat		N/A+14.0%£27.94MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 9/29/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel